Systemic therapies for metastatic pancreatic neuroendocrine tumors Review
| Authors: | Hauser, H.; Gerson, D. S.; Reidy-Lagunes, D.; Raj, N. |
| Review Title: | Systemic therapies for metastatic pancreatic neuroendocrine tumors |
| Abstract: | Over the years, there have been significant advances in systemic treatments for metastatic pancreatic neuroendocrine tumors (panNETs). Despite these advancements, uncertainty remains regarding how to best sequence available therapies. For well-differentiated and metastatic panNETs that are somatostatin receptor (SSTR) avid on functional imaging, first-line therapy typically consists of somatostatin analogs (SSAs), given their favorable toxicity profile and overall low burden for patients. When progression of disease is observed on an SSA, multiple treatment options are available, including the targeted agents everolimus and sunitinib, peptide receptor radionuclide therapy (PRRT), as well as chemotherapy, with the latter often preferred for those panNETs of heavy tumor burden, higher grade, and/or more aggressive behavior clinically and/or radiographically. Here, we review panNET classification, currently available systemic treatments, therapy sequencing, and areas of active investigation to further our treatments for the disease. © 2019, Springer Science+Business Media, LLC, part of Springer Nature. |
| Keywords: | cancer chemotherapy; gene mutation; overall survival; neutropenia; review; bevacizumab; cisplatin; fluorouracil; placebo; sunitinib; systemic therapy; unspecified side effect; drug targeting; capecitabine; chemotherapy; temozolomide; carboplatin; dacarbazine; metastasis; progression free survival; multiple cycle treatment; bone marrow suppression; thrombocytopenia; genetic association; lymphocytopenia; acute leukemia; myelodysplastic syndrome; isotope labeling; folinic acid; nausea and vomiting; octreotide; oxaliplatin; indium 111; tumor classification; everolimus; angiopeptin; targeted agents; somatostatin receptor; streptozocin; pancreas islet cell tumor; molecularly targeted therapy; yttrium 90; gastroenteropancreatic neuroendocrine tumor; lutetium 177; human; prrt; oxodotreotide lu 177; pancreatic neuroendocrine tumors (pannets); somatostatin analogs (ssas) |
| Journal Title: | Current Treatment Options in Oncology |
| Volume: | 20 |
| Issue: | 12 |
| ISSN: | 1527-2729 |
| Publisher: | Springer |
| Date Published: | 2019-12-01 |
| Start Page: | 87 |
| Language: | English |
| DOI: | 10.1007/s11864-019-0690-x |
| PUBMED: | 31776785 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work